MATTHEW KRASUCKI
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry GLENDALE, WI NPI 1497920995
Browse related groups: Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry WI Axsome Therapeutics, Inc. All categories
General Payments — all program years on this page
$749.78
- Category: General Payments
- Program years: PY2018–2024
- Record count: 13
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $294.45 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $294.45 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Axsome Therapeutics, Inc. | $154.88 | 2 |
| Alkermes, Inc. | $82.59 | 3 |
| E.R. Squibb & Sons, L.L.C. | $22.69 | 1 |
| Neurocrine BioSciences, Inc. | $20.44 | 1 |
| Teva Pharmaceuticals USA, Inc. | $13.85 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1101410159 | E.R. Squibb & Sons, L.L.C. | $22.69 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1120535727 | Alkermes, Inc. | $25.51 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1120535729 | Alkermes, Inc. | $28.68 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1120535731 | Alkermes, Inc. | $28.40 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1148303160 | Axsome Therapeutics, Inc. | $32.28 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1148303162 | Axsome Therapeutics, Inc. | $122.60 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1150856750 | Neurocrine Biosciences, Inc. | $20.44 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1151607000 | Teva Pharmaceuticals USA, Inc. | $13.85 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.